Open AccessValidation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization
Author(s) -
Zhe-Xuan Wang,
Jing Li,
Enxin Wang,
Dongdong Xia,
Wei Bai,
Qiuhe Wang,
Jie Yuan,
Xiaomei Li,
Jing Niu,
Zhihua Yin,
Jielai Xia,
Daiming Fan,
Guohong Han
Publication year - 2020
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v26.i15.1805
Subject(s) - hepatocellular carcinoma , medicine , carcinoma , gastroenterology , radiology
Transarterial chemoembolization (TACE) is recommended for patients with intermediate hepatocellular carcinoma (HCC) according to treatment guidelines. However, a large number of patients with advanced HCC also receive TACE in clinical practice, especially for those with liver-confined HCC and Eastern Cooperative Oncology Group score (ECOG) 1. In view of previous studies, such patients have different prognoses from advanced HCC patients with macrovascular invasion or extrahepatic spread; therefore, patients with ECOG 1 alone might be classified into the intermediate stage and benefit from TACE treatment, but a study particularly focusing on such patients and exploring the effectiveness of TACE therapy is lacking.